Roxcef injection

Cefuroxime
Injection
Description:

Cefuroxime is a bactericidal second generation cephalosporin antibiotic which is active against a wide range of Gram-positive and Gram-negative susceptible organisms including many beta-lactamase producing strains. Cefuroxime inhibits bacterial cell wall synthesis by interfering with the transpeptidation process.


  • Composition

    Roxcef 250 Tablet: Each film coated tablet contains Cefuroxime Axetil BP equivalent to Cefuroxime 250 mg.

    Roxcef 500 Tablet: Each film coated tablet contains Cefuroxime Axetil BP equivalent to Cefuroxime 500 mg.

    Roxcef 750 mg IM/IV injection: Each vial contains Cefuroxime sodium USP equivalent to Cefuroxime 750 mg.

    Roxcef 1.5 g IV injection: Each vial contains Cefuroxime sodium USP equivalent to Cefuroxime 1.5 gm.
  • Indication

    It is indicated for the treatment of infections caused by sensitive bacteria.
    1. Pharyngitis/Tonsillitis caused by Streptococcus pyogenes.
    2. Acute Bacterial Otitis Media caused by Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis (beta-lactamase producing strains) or Streptococcus pyogenes.
    3. Acute bacterial maxillary sinusitis caused by Streptococcus pneumoniae or Haemophilus influenzae (non beta-lactamase producing strains)
    4. Lower respiratory tract infections including pneumoniae, caused by Streptococcus pneumoniae, Haemophilus influenzae (including beta lactamase-producing strains), Klebsiella spp., Staphylococcus aureus (penicillinase- and non-penicillinase-producing strains), Streptococcus pyogenes, E. coli
    5. Acute bacterial exacerbation of chronic bronchitis and Secondary bacterial infections of Acute bronchitis caused by Streptococcus pneumoniae, Haemophilus influenzae (beta-lactamase negative strains) or Haemophilus parainfluenzae (beta-lactamase negative strains).
    6. Skin and skin-structure infections caused by Staphylococcus aureus (including beta-lactamase producing strains) or Streptococcus pyogenes.
    7. Urinary tract infections caused by E.coli or Klebsiella pneumoniae.
    8. Bone and Joint Infections caused by Staphylococcus aureus (penicillinase- and non-penicillinase-producing strains).
    9. Gonorrhoea caused by penicillinase-producing and non-penicillinase producing strains of Neisseria gonorrhoeae.
    10.Early Lyme Disease (erythema migrans) caused by Borrelia burgdorferi.
  • Dosage & Administration

  • Contraindication

    Cefuroxime is contraindicated in patients with known allergy to Cephalosporins.
  • Precaution

    Cefuroxime should be given with care to patients receiving concurrent treatment with potent diuretics & who has history of colitis. Cephalosporin antibiotics may in general be given safely to patients who are hypersensitive to penicillin although cross reactions have reported. Cefuroxime has shown, that is not likely to be a problem at the recommended to dose levels.
  • Side Effects

    Adverse effects to Cefuroxime have occurred infrequently and have been generally mild and transient in nature. Effects reported include rashes and gastrointestinal disturbances. As with other antibiotics, prolonged use may result in the overgrowth of non susceptible organisms e.g. Candida.
  • Drug Interaction

    No potentially hazardous interactions have been reported.
  • Overdose

  • Pregnancy & Lactation

    US FDA pregnancy category of Cefuroxime is B. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. Cefuroxime have been shown to be excreted in human milk. So, caution should be exercised when Cefuroxime is administered to a nursing woman.
  • Storage Condition

    Store in a cool, dry place (below 30o C), away from light & moisture. Keep out of the reach of children.
  • How Supplied

    Roxcef 250 Tablet: Each box contains 12 tablets in Alu-Alu blister pack. Roxcef 500 Tablet: Each box contains 6 tablets in Alu-Alu blister pack. Roxcef 750 mg IV/IM Injection: Each Combipack contains one vial containing Cefuroxime Sodium USP equivalent to Cefuroxime 750 mg, one ampoule of 10 ml of Water for Injection USP, one 10 ml disposable syringe and a butterfly needle. Roxcef 1.5 g IV Injection: Each Combipack contains one vial containing Cefuroxime Sodium USP equivalent to Cefuroxime 1.5 gm, two ampoules of 10 ml of Water for Injection USP, one 20 ml disposable syringe and a butterfly needle.